Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Procter & Gamble Health Limited

NSE: PGHLPharmaceuticals

Share price

₹5,156.50

-1.48% close of 8 Oct 2026

Market cap ₹8,766 CrP/E 24.5

Business score

How strong the business is, in one number. The parts behind it are in Pro.

70

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹8,766 Cr

P/E ratio

24.5

P/B ratio

16.3

ROCE

83.9%

ROE

61.6%

Dividend yield

3.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹6,918.5052-week low ₹4,778.60

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 12.6% over the past year, and 7.1% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 24.1% to 32.6% over the last four years.

Whether it grew faster than its sector

It grew 7.1% a year against a sector median of 13.1% — 6.0 percentage points slower.

Room to re-rate, or risk of de-rating

At 24.5× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 37.3×, the 0th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.3 times its growth rate, on earnings growth of 19%.

Profit growthPrice per ₹1 profitPer 1% growth
Procter & Gamble Health Limited — this one19%/yr24.5×₹1.3
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 3 of 130 on returns, 91 of 127 on growth, 16 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 83.9% on capital, ahead of 98% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1141 crore of cash from the business, spent ₹112 crore on plant and equipment, and returned ₹1384 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 11 years, about 65 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 17 days for its cash to waiting 30 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit jumped 46% to ₹96 crore on 7% revenue growth

Announced 6 Aug 2026 · Standalone · Unaudited

Revenue

₹364 Cr

Revenue vs last year

+7.3%

Revenue vs last quarter

-1.7%

Net profit

₹96 Cr

Profit vs last year

+45.7%

Profit vs last quarter

+1.2%

Net margin

26.4%

EPS

₹57.92

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹8,766 Cr
Prev close
₹5,156.50
52w High
₹6,975
52w Low
₹4,707
Enterprise value
₹8,590 Cr
Beta
0.5
Price CAGR 1y
-16.0%
Price CAGR 3y
1.0%
Price CAGR 5y
-2.0%
Price CAGR 10y
22.0%

Ratios

Return on assets
38.9%
PEG ratio
1.4
P/E ratio
24.5
P/B ratio
16.3
EV / EBITDA
18.4
Industry P/E
38.0
ROCE
83.9%
ROCE 5y average
52.0%
ROE
61.6%
Debt / Equity
0.0
Interest coverage
451.0
Dividend yield
3.0%
ROE 3y average
43.0%
ROE last year
62.0%

Annual P&L

Annual revenue
₹1,408 Cr
Annual profit
₹327 Cr
Operating margin
33.0%
Net profit margin
23.2%
EBITDA margin
32.6%
Sales growth 3y
4.6%
Sales growth 5y
6.9%
Profit growth 3y
19.0%
Profit growth 5y
5.0%
EPS
₹197
Sales growth TTM
13.0%
Profit growth TTM
11.0%
Dividend payout
104.0%

Quarter P&L

Sales latest quarter
₹364 Cr
Profit latest quarter
₹96 Cr
YoY quarterly sales growth
7.4%
YoY quarterly profit growth
45.5%
OPM latest quarter
27.4%

Balance Sheet

Book Value
₹309
Face Value
₹10.0
Total debt
₹9 Cr
Total cash
₹185 Cr
Borrowings
₹9 Cr
Reserves / Equity
29.9

Cash Flow

Operating cash flow
₹338 Cr
Free cash flow
₹323 Cr
FCF yield
3.7%
Net cash flow
-₹5 Cr

Shareholding

Promoter holding
51.8%
FII holding
6.3%
DII holding
12.4%
Public holding
29.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,763.7533.54,23,1830.902,901.26.015,299.910.520.5
Divi's Lab.9,449.0084.22,50,8410.31902.065.53,080.027.822.0
Torrent Pharma.4,628.0078.91,76,0340.81566.05.84,921.054.915.2
Zydus Lifesci.1,117.5022.91,11,4710.09990.2-35.18,017.022.021.1
Laurus Labs2,019.0099.81,09,0890.10362.1125.52,026.329.117.8
Cipla1,303.0029.41,05,2660.98785.6-39.27,119.32.315.5
Mankind Pharma2,403.6046.599,2800.04574.129.64,030.612.913.5
P & G Health Ltd5,180.0025.88,5982.9996.29.5363.77.483.9
Median416.7034.12,1310.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales301305310252284313310311339325374370364
Expenses256216208185236199186230248205263235264
Material Cost916078848580
Change in Inventories-5.8210-2012-15-8.65
Purchases of Stock-in-Trade142411132225
Employee Cost495654625160
Other Expenses8398829291108
Operating Profit458910267481141238190120110136100
OPM %15293327173640262737303727
Other Income5652-18343454436
Exceptional items (within Other Income)0000032
Interest0000000000000
Depreciation6677766556666
Profit before tax448810063231111227989119109133129
Tax %32262826262625222526292926
Net Profit30667247178291616689789596
EPS in Rs18404328105055374053475758
Diluted EPS in Rs374053475758

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025 9mMar 2026TTM
Sales9409936988499271,3561,0091,1141,2301,1519341,4081,433
Expenses8558776217017231,037762846905845616949967
Material Cost307
Change in Inventories-13
Purchases of Stock-in-Trade71
Employee Cost223
Other Expenses364
Operating Profit8511677148204319246268325307319459466
OPM %9121117222424242627343333
Other Income2224747684866181318-5101549
Exceptional items (within Other Income)0
Interest000000101100.551
Depreciation23251921172930272827172424
Profit before tax83115132895234355233253314273312450490
Tax %36312963228242427262527
Net Profit547994839159254177193229201234327357
EPS in Rs32485750596153107116138121141197215
Diluted EPS in Rs197
Dividend Payout %232327870150122456921589104

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
4%
5 years
7%
3 years
5%
TTM
13%

Compounded profit growth

10 years
20%
5 years
5%
3 years
19%
TTM
11%

Stock price CAGR

10 years
22%
5 years
-2%
3 years
1%
1 year
-16%

Return on equity

10 years
31%
5 years
35%
3 years
43%
Last year
62%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Equity Capital171717171717171717171717
Reserves5756477171,524800890687600734522520508
Borrowings00000083121089
Other Liabilities192215258219250269275269338247250308
Total Liabilities7848799911,7591,0671,1769868881,101794794841
Fixed Assets132111115104101101104112144128116102
CWIP730917112139413261114
Investments422870000000000
Other Assets6037117971,6399541,053843736925660667726
Total Assets7848799911,7591,0671,1769868881,101794794841

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Cash from Operating Activity8310754-130235247170236228169338
Cash from Investing Activity-68-75-481,270165-32-26-22-7101
Cash from Financing Activity-12-15-22-30-883-387-289-98-418-235-344
Net Cash Flow417-161,109-483-172-145116-197-56-5
Free Cash Flow387524-157212196132198207168324

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemDec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Debtor Days493964283026222734275743
Inventory Days140145243154139113138124136120152137
Days Payable5567128124106105209185239184239192
Cash Conversion Cycle134118179586334-49-34-69-37-30-13
Working Capital Days69529442222371715194830
ROCE %151816782029293845454884

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters525252525252525252525252
FIIs7.387.606.246.396.617.016.866.997.246.976.206.33
DIIs121314151515141414141412
Public292828272726272727272829
No. of Shareholders57,91956,73056,77855,92354,79253,73653,99352,47850,00649,30250,88349,056

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -15.1% (₹6,072.50 → ₹5,156.50)Brick size ₹148.35 (fixed)Bricks 31
₹6,000₹5,157Nov '25Feb '26May '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹5,156.50 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-176inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,10,34,483inr

2026-03-31

News

News and filings about Procter & Gamble Health Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Pyridoxine hydrochloride (Vitamin B6) IP/EP
  • Raw and packing materials
  • Thiamine hydrochloride (Vitamin B1) IP/EP
  • Vitamin B12 and derivatives
  • Vitamin E IP / vitamin E derivatives

Buys drug ingredients from

  • Jiangxi Tianxin Pharmaceutical Co Ltd
  • Kenko Corporation
  • Procter & Gamble International Operations SA Geneva
  • Procter & Gamble International Operations SA Singapore Branch
  • Zhejiang Medicine Co Ltd

Sells to

  • Emerchemie NB Ceylon Ltd · vitamin/VMS products (Sri Lanka distribution)
  • Nikhil Pharma Pvt Ltd · syrup, tablets and vitamin/thiamine products
  • P&G Health Austria GmbH & Co. OG · pharmaceutical/VMS products (group export)

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE199A01012

Plants

  • Procter & Gamble Health Limited Usgaon manufacturing site · Ponda / Usgaon, Goa

News impact

Big market events that reach Procter & Gamble Health Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

27 Aug 2026unspecified₹45
12 Feb 2026special₹50
12 Feb 2026interim₹110
22 Aug 2025unspecified₹45
21 Feb 2025interim₹80
28 Nov 2024unspecified₹60
14 Feb 2024special₹150
14 Feb 2024interim₹50

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.